These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis. Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432 [TBL] [Abstract][Full Text] [Related]
5. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype. Medwid S; Wigle TJ; Kim RB Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798 [TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945 [TBL] [Abstract][Full Text] [Related]
7. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938 [TBL] [Abstract][Full Text] [Related]
8. Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population. Saarenheimo J; Wahid N; Eigeliene N; Ravi R; Salomons GS; Ojeda MF; Vijzelaar R; Jekunen A; van Kuilenburg ABP Cancer Chemother Pharmacol; 2021 May; 87(5):657-663. PubMed ID: 33544210 [TBL] [Abstract][Full Text] [Related]
9. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD. Knikman JE; Zhai Q; Lunenburg CATC; Henricks LM; Böhringer S; van der Lee M; de Man FM; Offer SM; Shrestha S; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; van Schaik RHN; Gelderblom H; Mathijssen RHJ; Schellens JHM; Cats A; Guchelaar HJ; Swen JJ Genome Med; 2024 Aug; 16(1):101. PubMed ID: 39148102 [TBL] [Abstract][Full Text] [Related]
11. de With M; Brufau G; van den Berg LA; de Man FM; Trajkovic M; Thijs MF; Castel R; Vermeer HJ; El Bouazzaoui S; van Hemel A; Matic M; Mathijssen RHJ; Bins S; van Schaik RHN JCO Precis Oncol; 2022 Jul; 6():e2200180. PubMed ID: 35862869 [TBL] [Abstract][Full Text] [Related]
12. Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a Ockeloen CW; Raaijmakers A; Hijmans-van der Vegt M; Bierau J; de Vos-Geelen J; Willemsen AE; van den Bosch BJ; Coenen MJ J Oncol Pharm Pract; 2023 Jan; 29(1):5-13. PubMed ID: 34797200 [TBL] [Abstract][Full Text] [Related]
13. Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction. Medwid S; Wigle TJ; Ross C; Kim RB Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686089 [TBL] [Abstract][Full Text] [Related]
14. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765 [TBL] [Abstract][Full Text] [Related]
15. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102 [TBL] [Abstract][Full Text] [Related]
16. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre. Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114 [TBL] [Abstract][Full Text] [Related]
17. A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report. Malekkou A; Tomazou M; Mavrikiou G; Dionysiou M; Georgiou T; Papaevripidou I; Alexandrou A; Sismani C; Drousiotou A; Grafakou O; Petrou PP BMC Med Genomics; 2024 Mar; 17(1):78. PubMed ID: 38528593 [TBL] [Abstract][Full Text] [Related]